Open AccessAssociation of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF ‐targeted therapies
Author(s) -
Patel Gargi S.,
Ullah Shahid,
Beeke Carol,
Hakendorf Paul,
Padbury Robert,
Price Timothy J.,
Karapetis Christos S.
Publication year - 2015
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.490
Subject(s) - medicine , overweight , underweight , hazard ratio , bevacizumab , body mass index , population , chemotherapy , oncology , colorectal cancer , cancer , confidence interval , environmental health
Abstract Although a raised body mass index ( BMI ) is associated with increased risk of colorectal cancer ( CRC ) and recurrence after adjuvant treatment, data in the metastatic setting is limited. We compared overall survival ( OS ) across BMI groups for metastatic CRC , and specifically examined the effect of BMI within the group of patients treated with targeted therapies ( TT ). Retrospective data were obtained from the South Australian Registry for mCRC from February 2006 to October 2012. The BMI at first treatment was grouped as underweight <18.5 kg/m 2 , Normal = 18.5 to <25 kg/m 2 , Overweight = 25 to <30 kg/m 2 , Obese I = 30 to <35 kg/m 2 , Obese II ≥35 kg/m 2 . Of 1174 patients, 42 were underweight, 462 overweight, 175 Obese I, and 77 Obese II . The OS was shorter for patients who were underweight and overweight compared to normal ( OS 13.7 and 22.3 vs. 24.1 months, respectively, hazard ratio [ HR ] 2.21 and 1.23). The adjusted median OS was longer for normal versus overweight or obese I patients receiving chemotherapy + targeted therapy (35.7 vs 25.1 or 22.8 months, HR 1.59 and 1.63, respectively) with no difference in OS for chemotherapy alone. On breakdown by type of targeted therapy, overweight and obese I patients had a poorer outcome with Bevacizumab. The BMI is predictive of a poorer outcome for underweight and overweight patients in the whole population. Of those receiving chemotherapy and targeted therapy, BMI is an independent predictor for OS for overweight and obese I patients, specifically for those treated with Bevacizumab. Patients who are overweight or obese (group I) may be a target group for lifestyle and nutrition advice to improve OS with TT .